WO1998022465A1 - A1 adenosine receptor antagonists - Google Patents
A1 adenosine receptor antagonists Download PDFInfo
- Publication number
- WO1998022465A1 WO1998022465A1 PCT/US1997/021045 US9721045W WO9822465A1 WO 1998022465 A1 WO1998022465 A1 WO 1998022465A1 US 9721045 W US9721045 W US 9721045W WO 9822465 A1 WO9822465 A1 WO 9822465A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- integer ranging
- alkyl
- assay
- type probe
- Prior art date
Links
- 0 *c1nc(N(*)C(N(*)C2=O)=O)c2[n]1* Chemical compound *c1nc(N(*)C(N(*)C2=O)=O)c2[n]1* 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to novel compounds useful as A] adenosine receptor antagonists.
- Adenosine receptors are involved in a vast number of peripheral and central regulatory mechanisms such as, for example, vasodilation, cardiac depression, inhibition of lipolysis, inhibition of insulin release and potentiation glucagon release in the pancreas, and inhibition of neurotransmitter release from nerve endings.
- adenosine receptors can be divided into two main classes, Ai receptors which can inhibit, and A 2 receptors which can stimulate adenylate cyclase activity.
- Ai receptors which can inhibit
- a 2 receptors which can stimulate adenylate cyclase activity.
- One of the best known classes of adenosine receptor antagonists are the xanthines which include caffeine and theophylline. See e.g., Muller et al., J. Med. Chem. 33: 2822-2828 (1990). In general, many of these antagonists often suffer from poor water solubility, and low potency or lack of selectivity for adenosine receptors. Additionally, selective analogues of adenosine receptor antagonists have been developed through the "functionalized congener" approach.
- Analogues of adenosine receptor ligands bearing functionalized chains have been synthesized and attached covalently to various organic moieties such as amines and peptides. Attachment of the polar groups to xanthine congeners has been found to increase water solubility. Nonetheless, such developments have yet to fully address problems associated with potency and selectivity. More recently Jacobson et al. J. Med. Chem. 35: 408-422 (1992) has proposed various derivatives of adenosine and theophylline for use as receptor antagonists. The article discloses that hydrophobic substituents are able to potentially enhance affinity.
- the present invention provides a compound of the general formula:
- R] is selected from the group consisting of C ⁇ -C 8 alkyl; R 2 is of the formula:
- n is an integer ranging from 1 to 8;
- R 5 is H or CH 3 (CH ) P , wherein p is an integer ranging from 1 to 7; and R 6 is H, (CH ) m H, or (CH 2 ) m OH, wherein m is an integer ranging from 1 to 8;
- R is selected from the group consisting of:
- q is an integer ranging from 1 to 8;
- D is selected from the group consisting of S, NH, and O; and wherein R 7 is selected from the group consisting of H, OH, NH 2 , R 9 COOH, wherein R 9 is an alkylene or alkenylene group having 1 to 8 carbon atoms, and (CH 2 ) t OH, wherein t is an integer ranging from 1 to 8;
- Ri 1 is selected from the group consisting of-CH 2 COOH and -CH 2 -CONH(CH 2 ) w NHZ, wherein w is an integer ranging from 1 to 2 and Z is selected from the group consisting of hydrogen and acetate; and
- R 4 is of the formula:
- R is selected from the group consisting of H; OH; (CH 2 ) f NH 2 wherein f is selected from the group consisting of 0 and an integer ranging from 1 to 8; (CH 2 ) s OH, wherein s is an integer ranging from 1 to 8; and RioCOOH, wherein Rio is an alkylene or alkenylene group having 1 to 8 carbon atoms; and r is an integer ranging from 1 to 8.
- the invention provides for assay-type probes of the above compound, wherein the probes are marked or conjugated with radioactive or non-radioactive material.
- the invention provides a pharmaceutically acceptable salt of the above compound.
- the invention provides a pharmaceutical composition which comprises the above compound and a pharmaceutically acceptable carrier.
- the present invention is directed to a compound of the formula (I):
- Ri is selected from the group consisting of C]-C 8 alkyl, preferably Ci to C 4 alkyl.
- R] is more preferably d or C 3 alkyl, and is most preferably C 3 alkyl.
- R 2 is of the formula:
- n is an integer ranging from 1 to 8, more preferably 1 to 4
- R 5 is H or CH 3 (CH 2 ) P , wherein p is an integer ranging from 1 to 7, more preferably 1 to 4
- R 6 is H, (CH ) m H, or (CH 2 ) m OH, wherein m is an integer ranging from 1 to 8, more preferably 1 to 4.
- R 3 is selected from the group consisting of:
- the alkylene or alkenylene groups may be substituted or unsubstituted.
- Ri 1 is selected from the group consisting of -CH 2 COOH and -CH 2 -CONH(CH 2 ) w NHZ, wherein w is an integer ranging from 1 to 2 and Z is selected from the group consisting of hydrogen and acetate.
- R 4 is of the formula:
- R 8 is selected from the group consisting of H; OH; (CH 2 ) f NH , wherein f is selected from the group consisting of 0 and an integer ranging from 1 to 8; (CH ) s OH, wherein s is an integer ranging from 1 to 8, more preferably 1 to 4; and RioCOOH, wherein Rio is an alkylene or alkenylene group having 1 to 8 carbon atoms; and r is an integer ranging from 1 to 8, more preferably 1 to 4.
- R is of the formula:
- R) is C 3 alkyl;
- R 5 is CH 3 (CH 2 ) P wherein p is 1;
- R 6 is (CH ) m OH wherein m is 2;
- R 7 is H;
- R 8 is NH 2 ;
- f is 0;
- n is 2;
- m is 2;
- q is 1 ; and
- r is 2.
- Ri is C 3 alkyl; R 5 is CH (CH ) P wherein p is 1 ; R 6 is H; R 7 is NH ; R 8 is NH ; f is 0; n is 2; q is 1 ; and r is 2.
- Ri is C alkyl; R 5 is CH (CH 2 ) P wherein p is 1 ; R 6 is H; R 7 is H; R 8 is NH 2 ; f is 0; n is 2; q is 1 ; and r is 2.
- Ri is C 3 alkyl
- R 5 is CH 3 (CH 2 ) P wherein p is 1
- R 6 is H
- R 7 is H
- n is 2
- q is 1
- r is 2.
- Ri is C 3 alkyl
- R 5 is CH (CH 2 ) P wherein p is 1
- R 6 is H
- R 8 is NH 2
- f is 0
- n is 2
- q is 1
- r is 2.
- the compound of the present invention may form pharmaceutically acceptable salts with both organic and inorganic acid and bases.
- suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, ascorbic, maleic, methanesulfonic, and the like. Any of the amine acid addition salts may also be used.
- the salts are prepared by contacting the free base form of the compound with an appropriate amount of the desired acid in a manner known to one skilled in the art.
- suitable bases for salt formation are sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, calcium hydroxide, ammonia, organic amines, and the like.
- the salts may be prepared by contacting the free acid form of the compound with an appropriate amount of the desired base in a manner known to one skilled in the art.
- the invention also provides Ai adenosine receptor antagonist compounds with radioactive or non-radioactive labels.
- Such labelled compounds are useful as assay-type probes or conjugates, and may be used to obtain quantitative binding measurements of the Ai adenosine receptor antagonist compounds.
- assay-type probes refers to those materials which are useful for enhancing the selectivity of the quantitative analysis of the Ai adenosine receptor compounds of the invention. Examples of such assay-type probes are described in U.S. Patent No. 5,248,770 to Jacobson et al., the disclosure of which is incorporated herein by reference in its entirety. The probes are highly useful in that they have little adverse effect on the affinity of the compounds of the present invention.
- Radioactive markers include, but are not limited to, an electric spin marker, a I9 F NMR probe, a radioactive 18 F isotope marker, a radioactive iodine marker (e.g., I), a radioactive H marker, tritium, and a complex of a metal atom or a metal ion and a chelating agent.
- An exemplary metal ion is a radioactive isotope of technetium or indium.
- An exemplary chelating agent is diethylene pentacetic anhydride.
- Non-radioactive materials may be used in labelling the present Aj adenosine receptor compounds.
- Numerous examples are presented in U.S. Patent No. 5,248,770 to Jacobson et al. Biotin is used as a common non-radioactive label for such probes, as described in R.W. Old et al. Principals of Gene Manipulation, 4th ed: 328-331 (1989).
- a spacer component may be added to the compound according to an accepted method. Such a method is described in the Jacobson et al. '770 patent.
- Exemplary spacer components include, but are not limited to, an oligopeptide, triglycidyl, and N-hydroxysuccinimide ester.
- Biotin may be bonded to any suitable linkage provided by substituents on the compound structure in accordance with any accepted and suitable technique.
- biotin may be bonded to the hydroxy group on R 6 when the compound contains (CH ) m OH at R 6 with m defined herein; to the amino group present on either of R 7 or R 8 when (CH ) f NH 2 is contained at the R 8 position, wherein f is defined herein; to the hydroxyl group present as R 7 or R 8 ; or to the carboxyl group present when R 7 and R 8 are RgCOOH or RioCOOH respectively, with R 9 and Rio defined herein.
- the biotin may be bonded to a hydroxyl group present on R 8 , when R 8 is
- Biotin may also be bonded to R 7 , when R 7 is (CH 2 ) t OH with t being defined herein.
- the biotin-labeled probes may be detected through appropriate and known analytical techniques.
- Fluorescent dyes may also be employed as a non-radioactive labels and are applied to appropriate locations on the compounds of the invention. Such dyes include, but are not limited to, tetramethylrhodamine, fluorescein isothiocyanate, and mixtures thereof.
- Other non-radioactive materials include for example, nitrobenzoxadiazole; 2,2,6,6-tetramethyl- piperindinyloxy-4-isothiocyanate; and mixtures thereof.
- the invention is also directed to a pharmaceutical composition which includes the compound of the present invention and a pharmaceutically acceptable carrier.
- the pharmaceutical composition is particularly useful in applications relating to organ preservation in vivo or in situ, perfusion of an isolated organ either removed or contained within the body (e.g., when an organ is transported for transplantation), cardiopulmonary bypass, perfusion of an extremity or limb, and the like.
- the compounds may be used in intra-articular, intra-thecal, gastrointestinal, and genital urinary applications, as well as in any cavity or lumen such as, for example, the thoracic cavity or ear canal.
- the pharmaceutical composition may be employed, as an example, in oral dosage form as a liquid composition.
- Such liquid compositions can include suspension compositions or syrup compositions and can be prepared with such carriers as water; a saccharide such as sucrose, sorbitol, fructose, and the like; a glycol such as poly ethyl eneglycol, polypropyleneglycol, and the like; an oil such as sesame oil, olive oil, soybean oil, and the like; an antiseptic such as p-hydroxy- benzoic acid esters and the like; and a flavor component such as a fruit flavor or a mint flavor.
- the pharmaceutical composition may also be in the form of powder, pills, capsules, and tablets and can be prepared with various carriers.
- Suitable carriers include, but are not limited to, lactose, glucose, sucrose, mannitol, and the like; disintegrators such as starch, sodium alginate, and the like; binders such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin, and the like; surfactants such as, for example, fatty acid esters; and plasticizers such as, for example, glycerins.
- the composition of the present invention is especially useful when applied sublingually. It should be noted that in the preparation of the tablets and capsules, a solid pharmaceutical carrier is used.
- the pharmaceutical composition may be used in the form of, for example, eye drops or an aerosol.
- compositions may be employed in the form of a suppository, a nasel spray, and an injectable solution. These compositions are prepared using appropriate aqueous solutions which may include, but are not limited to, distilled water, and saline and buffer additives. Other components may be employed such as organic materials including neutral fatty bases. Additionally, the pharmaceutical composition may be utilized in a transdermal application.
- Biopolymers may be used as carriers in the above pharmaceutical compositions.
- Exemplary biopolymers may include, for example, proteins, sugars, or lipids.
- the Ai receptor antagonists of the present invention are particularly useful as, for example, anti-allergenics, CNS stimulants, diuretics, anti- asthmatics, and cardiotonics.
- the compounds advantageously display increased affinity at Ai receptor sites relative to former Ai receptor antagonists while simultaneously exhibiting good water solubility.
- Ai adenosine receptor antagonists of the present invention may be synthesized according to the process illustrated below:
- R' may be Cj-C 8 alkyl
- R" may be selected from the group consisting of H, OH, (CH 3 ) e NO 2 wherein e is selected from the group consisting of 0 and an integer ranging from 1 to 8
- R x may be selected from the group consisting of:
- R"' may be selected from the group consisting of H, OH, NO 2 , RgCOOH, wherein R 9 is an alkylene or alkenylene group having 1 to 8 carbon atoms, and (CH 2 ) t OH, wherein t is an integer ranging from 1 to 8;
- D may be selected from the group consisting of O, S, and NH;
- q is an integer ranging from 1 to 8;
- Rn is selected from the group consisting of - CH 2 COOH and -CH 2 -CONH(CH 2 ) w NHZ, wherein w is an integer ranging from 1 to 2 and Z is selected from the group consisting of hydrogen and acetate; and
- R' v may be selected from the group consisting of H, (CH 2 ) m H, and (CH 2 ) m OH, wherein m is an integer ranging from 1 to 8.
- R v may be selected from the group consisting of H; OH; (CH 2 ) f NH 2 wherein f is selected from the group consisting of 0 and an integer ranging from 1 to 8; (CH ) s OH, wherein s is an integer ranging from 1 to 8; and RioCOOH, wherein Rio is an alkylene or alkenylene group having 1 to 8 carbon atoms.
- R x ⁇ may be selected from the group consisting of:
- D may be selected from the group consisting of O, S, and NH; q is an integer ranging from 1 to 8; R vl may be selected from the group consisting of H, OH, NH , R 9 COOH, wherein R9 is an alkylene or alkenylene group having 1 to 8 carbon atoms, and (CH 2 ) t OH, wherein t is an integer ranging from 1 to 8.
- Ri i is selected from the group consisting of -CH 2 COOH and -CH 2 -CONH(CH 2 ) w NHZ, wherein w is an integer ranging from 1 to 2 and Z is selected from the group consisting of hydrogen and acetate.
- the above synthesis steps may be carried out at standard temperature and pressure conditions, optionally under reflux.
- An exception to this pertains to the reaction involving intermediates (VI) and (VII) which is preferably performed at a temperature ranging from about 25 °C to about 50°C and at atmospheric pressure.
- the reaction step involving intermediate (V) becoming intermediate (VI) it is desired to employ an oxidation step with FeCl 3 or NaIO 4 subsequent to the nitrobenzene reflux.
- R" and/or R 1 contain nitro groups
- a reaction step which involves applying H over a Pd/C catalyst is employed prior to the reaction with CH OH/HCl.
- the resulting product (VII) may be further processed and purified according to accepted procedures.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002264721A CA2264721C (en) | 1996-11-19 | 1997-11-19 | A1 adenosine receptor antagonists |
JP52380798A JP2001504491A (en) | 1996-11-19 | 1997-11-19 | A Lower 1 Adenosine receptor antagonist |
US09/269,055 US6489332B1 (en) | 1996-11-19 | 1997-11-19 | A1 adenosine receptor antagonists |
AU52615/98A AU5261598A (en) | 1996-11-19 | 1997-11-19 | A1 adenosine receptor antagonists |
DE69735108T DE69735108D1 (en) | 1996-11-19 | 1997-11-19 | A-1-ADENOSINE RECEPTOR ANTAGONIST |
EP97947567A EP0946557B1 (en) | 1996-11-19 | 1997-11-19 | A-1-adenosine receptor antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/753,048 US5786360A (en) | 1996-11-19 | 1996-11-19 | A1 adenosine receptor antagonists |
US08/753,048 | 1996-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998022465A1 true WO1998022465A1 (en) | 1998-05-28 |
Family
ID=25028936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/021045 WO1998022465A1 (en) | 1996-11-19 | 1997-11-19 | A1 adenosine receptor antagonists |
Country Status (8)
Country | Link |
---|---|
US (5) | US5786360A (en) |
EP (2) | EP1790651A1 (en) |
JP (1) | JP2001504491A (en) |
AT (1) | ATE315567T1 (en) |
AU (1) | AU5261598A (en) |
CA (1) | CA2264721C (en) |
DE (1) | DE69735108D1 (en) |
WO (1) | WO1998022465A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117445A (en) * | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
WO2003048120A2 (en) | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6800633B2 (en) | 1998-06-02 | 2004-10-05 | Osi Pharmaceuticals, Inc. | Pyrrolo[2,3d]pyrimidine compositions and their use |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
EP1601649A2 (en) * | 2003-02-19 | 2005-12-07 | Endacea Inc. | A1 adenosine receptor antagonists |
EP1636229A2 (en) * | 2003-06-06 | 2006-03-22 | Endacea, Inc. | A1 adenosine receptor antogonists |
EP1731520A1 (en) | 1999-12-02 | 2006-12-13 | OSI Pharmaceuticals, Inc. | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US7501407B2 (en) | 2001-12-20 | 2009-03-10 | Osi Pharmaceuticals, Inc. | Pyrimidine A2B selective antagonist compounds, their synthesis and use |
US7645754B2 (en) | 2001-12-20 | 2010-01-12 | Osi Pharmaceuticals, Inc. | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use |
US20110282031A1 (en) * | 2003-06-06 | 2011-11-17 | Wilson Constance N | A1 adenosine receptor diagnostic probes |
WO2017212425A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US5786360A (en) * | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
JP3563938B2 (en) | 1997-09-29 | 2004-09-08 | キヤノン株式会社 | Image reading apparatus and control method thereof |
GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
US6998404B2 (en) * | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
ES2528384T3 (en) | 2001-12-12 | 2015-02-09 | The Government Of The United States Of America, As Represented By The Secretary Department Of Healt | Methods of using adenosine receptor inhibitors to enhance the immune response and inflammation |
JP2007506804A (en) * | 2003-06-09 | 2007-03-22 | エンダセア, インコーポレイテッド | A1 adenosine receptor antagonist |
WO2006099204A1 (en) * | 2005-03-11 | 2006-09-21 | Aderis Pharmaceuticals, Inc. | Substituted 9-alkyladenines and the use thereof |
US7696211B2 (en) * | 2005-04-29 | 2010-04-13 | Wilson Constance N | Methods and pharmaceutical compositions for treating sepsis |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
JP2009529539A (en) * | 2006-03-07 | 2009-08-20 | エンダセア, インコーポレイテッド | Methods and compositions for treating respiratory disorders |
US20090048155A1 (en) | 2007-08-15 | 2009-02-19 | Endacea, Inc. | Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection |
EP2222676A4 (en) | 2007-12-21 | 2011-10-26 | Endacea Inc | A1 adenosine receptor antagonists |
US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
WO2011094208A2 (en) * | 2010-01-26 | 2011-08-04 | Endacea, Inc. | Methods and pharmaceutical compositions for preventing and treating renal impairment |
JP6043288B2 (en) | 2010-09-15 | 2016-12-14 | エンダセア, インコーポレイテッド | Methods of use and kits for the measurement of lipopolysaccharides by time-resolved fluorescence-based assays |
US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
CA3045508A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
JP2019536461A (en) | 2016-12-05 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Production of engineered cells for adoptive cell therapy |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
JP2020526194A (en) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | Mouse model for assessing toxicity associated with immunotherapeutic agents |
CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
KR20200116077A (en) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | Chimeric antigen receptor and coding polynucleotide specific for B cell maturation antigen |
CN111989106A (en) | 2017-12-01 | 2020-11-24 | 朱诺治疗学股份有限公司 | Methods of administering and regulating genetically engineered cells |
EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
WO2020092848A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
WO2020092854A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
JP2022513062A (en) | 2018-11-16 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | Methods of Dosing Manipulated T Cells to Treat B-Cell Malignancies |
JP2022513685A (en) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | Methods for Treatment with Adoptive Cell Therapy |
PE20212198A1 (en) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | ANTIBODIES AND CHIMERIC RECEPTORS OF SPECIFIC ANTIGENS TO ORPHAN RECEPTOR 1, RECEPTOR TYROSINE KINASE TYPE (ROR1) |
KR20230009386A (en) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods and uses for cell therapy engineered with chimeric antigen receptors targeting B-cell maturation antigens |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE636828A (en) * | ||||
EP0501379A2 (en) * | 1991-02-25 | 1992-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine compounds |
EP0503563A2 (en) * | 1991-03-12 | 1992-09-16 | Merrell Pharmaceuticals Inc. | Novel 8-substituted purines as selective adenosine receptor agents |
EP0764647A1 (en) * | 1995-09-25 | 1997-03-26 | Bayer Ag | Substituted xanthins |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3317533A (en) * | 1967-05-02 | Theophylline derivatives | ||
US2887468A (en) * | 1954-03-11 | 1959-05-19 | Eastman Kodak Co | Copolyesters of a glycol, a dicarboxylic acid and a hydroxy carboxylic acid |
US2887486A (en) | 1956-10-29 | 1959-05-19 | S E Massengill Company | Theophylline derivatives |
US3317433A (en) | 1958-10-23 | 1967-05-02 | Ncr Co | Heat rupturable capsules |
GB947495A (en) | 1960-04-22 | 1964-01-22 | Manuf Prod Pharma | New derivatives of dialkyl xanthines and the preparation thereof |
DE1245383B (en) | 1960-04-22 | 1967-07-27 | Manuf De Produits Pharma A Chr | Process for the preparation of 8-benzyltheophylline derivatives with basic substituents in the 7-position |
US3031451A (en) | 1960-07-21 | 1962-04-24 | Endo Lab | Salt of nicotinic acid |
US3309271A (en) * | 1963-08-30 | 1967-03-14 | Manuf Prod Pharma | Methods and composition for inducing choleresis |
AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
US4092417A (en) | 1976-12-08 | 1978-05-30 | Johann A. Wulfing | Theophylline salts of 5-methylisoxazole-3-carboxylic acid |
DE2659241A1 (en) | 1976-12-23 | 1978-07-06 | Josef Dipl Chem Dr Rer N Klosa | Xanthinol orotate - used as pharmaceutical e.g. to promote blood circulation or mental alertness, as a cosmetic or in veterinary medicine |
SE7810947L (en) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-ALKYLXANTHINES |
EP0011399A1 (en) | 1978-11-11 | 1980-05-28 | FISONS plc | N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them |
IT1195267B (en) | 1980-04-15 | 1988-10-12 | Abc Ist Biolog Chem Spa | THEOFILLINMETHYLSOXANANIC DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
DE3120909C2 (en) | 1980-06-05 | 1986-01-02 | A. Christiaens S.A., Brüssel/Bruxelles | Process for the preparation of 7- (N-ethyl-N-β-hydroxyethylaminoethyl) -8-benzyltheophylline (Bamifylline) |
DE3028273A1 (en) | 1980-07-25 | 1982-02-25 | Fa. Dr. Willmar Schwabe, 7500 Karlsruhe | 1.4; 3.6-DIANHYDRO-HEXIT-NITRATE SUBSTITUTED BY PURINE BASES |
US4769377A (en) | 1983-02-18 | 1988-09-06 | The Johns Hopkins University | Adenosine receptor antagonists |
US5248770A (en) * | 1984-10-26 | 1993-09-28 | The United States Of America, As Represented By The Department Of Health And Human Services | Molecular probes for adenosine receptors |
US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
US4612315A (en) * | 1984-10-26 | 1986-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives |
US4772607A (en) | 1986-05-20 | 1988-09-20 | Warner-Lambert Company | Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
IT1197516B (en) | 1986-12-24 | 1988-11-30 | Abc Ist Biolog Chem Spa | THEOFILLINMETYLANIC AND THEOFILLINMETYLDITIAN DERIVATIVES PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM |
US4968672A (en) * | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
US5066655A (en) | 1987-04-24 | 1991-11-19 | Whitby Research, Inc. | N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists |
US5192740A (en) * | 1987-12-21 | 1993-03-09 | University Of Alberta | Compositions and methods for improving cold tolerance in animals and humans |
US5032593A (en) | 1988-07-01 | 1991-07-16 | Marion Merrell Dow Inc. | Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines |
US5298508A (en) * | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
DE8817122U1 (en) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 6507 Ingelheim, De | |
JP2843634B2 (en) * | 1989-03-06 | 1999-01-06 | 協和醗酵工業株式会社 | Xanthine derivative |
US4971972A (en) * | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
US5256650A (en) | 1989-03-29 | 1993-10-26 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
IT1240843B (en) | 1990-05-24 | 1993-12-17 | Malesci Istituto Farmacobiologico | XANTHINIC DERIVATIVES 1-7 SUBSTITUTED FOR ANTIASMATIC ACTIVITY, THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, THEIR PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION. |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
DE69229257D1 (en) * | 1991-11-08 | 1999-07-01 | Kyowa Hakko Kogyo Kk | Xanthine derivatives for the treatment of dementia |
ATE216584T1 (en) * | 1992-07-08 | 2002-05-15 | Kyowa Hakko Kogyo Kk | XANTHINE DERIVATIVES AS ANTIDEPRESSANTS |
TW252044B (en) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
US5340813A (en) * | 1992-11-09 | 1994-08-23 | Cell Therapeutics, Inc. | Substituted aminoalkyl xanthine compounds |
US5395836A (en) * | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
US5786360A (en) * | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
-
1996
- 1996-11-19 US US08/753,048 patent/US5786360A/en not_active Expired - Lifetime
-
1997
- 1997-11-19 CA CA002264721A patent/CA2264721C/en not_active Expired - Fee Related
- 1997-11-19 EP EP06000239A patent/EP1790651A1/en not_active Withdrawn
- 1997-11-19 DE DE69735108T patent/DE69735108D1/en not_active Expired - Lifetime
- 1997-11-19 JP JP52380798A patent/JP2001504491A/en not_active Ceased
- 1997-11-19 US US09/269,055 patent/US6489332B1/en not_active Expired - Fee Related
- 1997-11-19 AU AU52615/98A patent/AU5261598A/en not_active Abandoned
- 1997-11-19 EP EP97947567A patent/EP0946557B1/en not_active Expired - Lifetime
- 1997-11-19 AT AT97947567T patent/ATE315567T1/en not_active IP Right Cessation
- 1997-11-19 WO PCT/US1997/021045 patent/WO1998022465A1/en active IP Right Grant
-
1998
- 1998-04-15 US US09/060,527 patent/US6117998A/en not_active Expired - Fee Related
-
2000
- 2000-05-03 US US09/564,011 patent/US6495687B1/en not_active Expired - Fee Related
-
2002
- 2002-02-27 US US10/083,836 patent/US20020082269A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE636828A (en) * | ||||
EP0501379A2 (en) * | 1991-02-25 | 1992-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine compounds |
EP0503563A2 (en) * | 1991-03-12 | 1992-09-16 | Merrell Pharmaceuticals Inc. | Novel 8-substituted purines as selective adenosine receptor agents |
EP0764647A1 (en) * | 1995-09-25 | 1997-03-26 | Bayer Ag | Substituted xanthins |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117445A (en) * | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US7429574B2 (en) | 1998-06-02 | 2008-09-30 | Osi Pharmaceuticals, Inc. | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
US6800633B2 (en) | 1998-06-02 | 2004-10-05 | Osi Pharmaceuticals, Inc. | Pyrrolo[2,3d]pyrimidine compositions and their use |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
EP1731520A1 (en) | 1999-12-02 | 2006-12-13 | OSI Pharmaceuticals, Inc. | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US7598252B2 (en) | 2000-12-01 | 2009-10-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A, receptors and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
EP2050751A1 (en) | 2001-11-30 | 2009-04-22 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
WO2003048120A2 (en) | 2001-11-30 | 2003-06-12 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
US7504407B2 (en) | 2001-11-30 | 2009-03-17 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
US7501407B2 (en) | 2001-12-20 | 2009-03-10 | Osi Pharmaceuticals, Inc. | Pyrimidine A2B selective antagonist compounds, their synthesis and use |
US7645754B2 (en) | 2001-12-20 | 2010-01-12 | Osi Pharmaceuticals, Inc. | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use |
EP1601649A4 (en) * | 2003-02-19 | 2009-03-04 | Endacea Inc | A1 adenosine receptor antagonists |
EP1601649A2 (en) * | 2003-02-19 | 2005-12-07 | Endacea Inc. | A1 adenosine receptor antagonists |
EP1636229A4 (en) * | 2003-06-06 | 2008-07-30 | Endacea Inc | A1 adenosine receptor antogonists |
EP1636229A2 (en) * | 2003-06-06 | 2006-03-22 | Endacea, Inc. | A1 adenosine receptor antogonists |
US20110282031A1 (en) * | 2003-06-06 | 2011-11-17 | Wilson Constance N | A1 adenosine receptor diagnostic probes |
WO2017212425A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
US11547704B2 (en) | 2016-06-08 | 2023-01-10 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
Also Published As
Publication number | Publication date |
---|---|
EP0946557A1 (en) | 1999-10-06 |
JP2001504491A (en) | 2001-04-03 |
ATE315567T1 (en) | 2006-02-15 |
AU5261598A (en) | 1998-06-10 |
EP1790651A1 (en) | 2007-05-30 |
CA2264721C (en) | 2006-07-04 |
US6489332B1 (en) | 2002-12-03 |
US6117998A (en) | 2000-09-12 |
US5786360A (en) | 1998-07-28 |
EP0946557B1 (en) | 2006-01-11 |
US6495687B1 (en) | 2002-12-17 |
DE69735108D1 (en) | 2006-04-06 |
CA2264721A1 (en) | 1998-05-28 |
US20020082269A1 (en) | 2002-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6489332B1 (en) | A1 adenosine receptor antagonists | |
US7902360B2 (en) | A1 adenosine receptor antagonists | |
Jacobson et al. | Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists | |
US7423041B2 (en) | A1 adenosine receptor antagonists | |
US4612315A (en) | Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives | |
JP2590120B2 (en) | 6-thioxanthine | |
EP0559893B1 (en) | Xanthine derivative | |
WO1999020626A1 (en) | Folic acid derivatives | |
US9522916B2 (en) | A1 adenosine receptor antagonists | |
US10239891B2 (en) | Compositions to detect remnant cancer cells | |
US20090068101A9 (en) | A1 Adenosine Receptor Antagonists | |
US20110282031A1 (en) | A1 adenosine receptor diagnostic probes | |
US10815265B2 (en) | Process for preparation of regadenoson and polymorphs thereof | |
CS262300B1 (en) | Dihydrochloride of 5-/2-(n,n-dimethylamino)-ethoxy/-7-/3-(n,n-dimethylamino)propyl-7-hydroxy-7h-benzo/c/fluoren and process for preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page |
Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2264721 Country of ref document: CA Ref country code: CA Ref document number: 2264721 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09269055 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997947567 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 523807 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997947567 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997947567 Country of ref document: EP |